A Roundup of Major Autoimmune Transactions in the First Half of 2025
Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.
Up to $13 billions! A Roundup of Major Autoimmune Transactions in the First Half of 2025.
In recent years, the successive approvals of two new drugs have once again brought a chemokine receptor into the spotlight. In 2023, the FDA approved Motixafortide (brand name Aphexda) in combination with long-acting G-CSF for hematopoietic stem cell mobilization in patients with multiple myeloma. Then in 2024, the FDA approved Mavorixafor (Xolremdi) for the treatment […]
CCR1 (C-C motif chemokine receptor 1) is a G protein-coupled receptor (GPCR) involved in inflammatory responses and immune cell migration. In recent years, with the deepening research on immune-related diseases and the tumor microenvironment, CCR1 has gradually emerged as an important therapeutic target for autoimmune diseases, tumors, and organ fibrosis. 1. Overview of CCR1 Chemokine monomers […]
Are you developing antibody-drug conjugates (ADCs)? Are you seeking a reliable and standardized method to evaluate antibody internalization? We are proud to introduce the DT3C Protein (Cat. No. AME100004) — a novel recombinant fusion protein designed to simulate ADC mechanisms and provide a fast, universal, and functional solution for antibody internalization assessment. 1. What is […]
DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled “De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors”
Acute myeloid leukemia (AML) is a complex and highly heterogeneous hematologic malignancy closely associated with various cytogenetic and chromosomal abnormalities. Among them, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are one of the most common genetic alterations. Studies have shown that approximately 25% of AML patients carry FLT3 internal tandem duplication mutations (FLT3-ITD), while about […]
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, the linker, and the payload. Previously, we summarized the research progress in bispecific ADCs. Here, we further consolidate the pipeline updates of dual-payload ADCs.
In the drug development efforts targeting complex diseases such as neuropsychiatric disorders, metabolic dysregulation, and cancer, the neuropeptide Y (NPY) receptor family is garnering increasing attention from researchers and pharmaceutical companies alike. As a typical subfamily of G protein-coupled receptors (GPCRs), NPY receptors not only regulate a variety of physiological processes but also play critical […]
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such as bispecific ADCs and dual-toxin ADCs, forming a unique landscape at the AACR meeting. Here, we summarize the key players and target pipelines in the bispecific ADC (BsADC) space, based on AACR data.
DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 CAS and 2025 PEGS.